CD93

Across TCGA pan-cancer cohorts, CD93 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD93 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD93 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD93 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where CD93 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.198	0.378	.002	46	view →
LUAD	DFS	Tertile	All	0.820	0.924	.019	10	view →
LSCC	DFS	Median	II,III,IV	0.860	0.966	.030	6	view →
CCRCC	DFS	Tertile	III,IV	0.806	0.515	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD93–PDAC (DFS)

Open the PDAC breakdown →